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ABSTRACT 
Quantification of drugs and their metabolites in animal biological fluids such as 
plasma and urine is a common practice in drug development within the pharmaceutical 
industry. As drug concentrations in biological fluids play a critical role in assessment of drug 
safety and efficacy, bioanalytical methods are required to be accurate and reproducible. 
Bioanalytical issues of chemosynthetic drugs, a frequent target of research and 
development in Japan, have been studied by many scientists. Among the issues, questions 
remain about the conversion of drugs and their metabolites. This is despite the considerable 
adverse impact of conversion issues on the accuracy and reproducibility of concentration data. 
The conversion issues are divided into Total Concentration Issue and Individual 
Concentration Issue. Total Concentration Issue is an issue a laboratory researcher encounters 
if the total concentrations of an analyte before and after conversion are determined, and 
Individual Concentration Issue is a group of issues a laboratory researcher faces if the 
concentration to be measured is an individual concentration (not total concentration) and the 
effect of conversion on analyte quantification has to be excluded. Individual Concentration 
Issue is further divided into two issues. Analyte Decrease Issue is an issue a laboratory 
researcher faces if the concentration of an analyte is observed to decrease and Non-analyte 
Interference Issue is an issue when the researcher manages the risk of overestimation of an 
analyte concentration due to the conversion of non-analytes (for example, metabolites of the 
analytes) to the analyte. 
Total Concentration Issue is recognized if a drug has conformers and the 
conformers are analyzed as a single component. Conformers form a bimodal peak under most 
HPLC conditions. This peak shape hinders establishment of the necessary lower limit of 
quantification and sufficient reproducibility. In addition, conversion during pretreatment and 
differences in physicochemical properties between conformers present additional difficulties 
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in the development of a reproducible pretreatment method. 
Analyte Decrease Issue is recognized when an attempt is made to stabilize an 
analyte to preclude the underestimation of analyte concentration due to conversion (including 
degradation) of analytes. While many stabilization methods have been reported, only a few 
will be effective for any individual analyte. This situation impedes the development of 
stabilization methods. 
Non-analyte Interference Issue is recognized when presence and stability of 
non-analytes in a study sample are examined in order to mitigate the risk of overestimation of 
analyte concentration due to conversion of non-analytes. Most laboratories do not extensively 
examine this potential interference from non-analytes, as it requires additional time and 
energy in method development, and is not required by regulatory agencies. 
In this research, to solve these three issues, the author constructed and applied three 
“workflows” (one workflow per issue) to three new drug candidates, ASP2151, ASP3258, and 
enzalutamide. “Workflows” are figures in which tasks such as experiments and data 
interpretation are placed in a proper order, and are prepared to solve issues effectively. The 
author constructed a workflow for the determination of the total concentration of conformers, 
which streamlines development of a pretreatment method and an HPLC method under which 
conformers form a single peak. The author then constructed a workflow for the stabilization 
of a convertible analyte in which the cause of conversion is estimated from analyte chemical 
structures etc. and used to prioritize stabilization methods to be examined experimentally. 
Finally, the author constructed a workflow for interference from convertible non-analytes to 
assess the possibility of interference in the early phase of method development by using 
available information including chemical structures of dosed drugs and analytes, and to 
accordingly take measures depending on the possibility of interference. 
When the workflow for the determination of the total concentration of conformers 
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was applied to ASP2151, an HPLC method and a pretreatment method were developed 
smoothly. The method validation results demonstrated that the method has the necessary 
lower limit of quantification and sufficient reproducibility. When the workflow for the 
stabilization of a convertible analyte was used in method development for enzalutamide 
metabolite M2, the workflow helped to determine that hydrolysis of an amide bond of M2 
could be stopped by the cooling of samples and addition of an esterase inhibitor. The 
workflow for interference from a convertible non-analyte was applicable for ASP2151, 
ASP3258, and enzalutamide and facilitated the employment of measure consistent with the 
possibility of interference. No interference from a non-analyte was observed in sample 
analysis, demonstrating that the workflow can identify and solve issues during method 
development using fewer resources than the currently available recommendation. Finally, the 
developed bioanalytical methods were applied to sample analysis of ASP2151, ASP3258, and 
enzalutamide and clarified absorption and concentration-time profiles. 
The three workflows established in the present research are expected to aid drug 
development, by solving all issues derived from the conversion of compounds and facilitating 
the development of accurate and reproducible bioanalytical methods. In addition, absorption 
and concentration-time profiles of ASP2151, ASP3258, and enzalutamide in animals were 
determined to support the development of these drug candidates. 
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